Perforated Gastric Ulcer Associated with Anti-Angiogenic Therapy
Anti-angiogenic therapy with bevacizumab, an inhibitor of vascular endothelial growth factor, is commonly used in metastatic colorectal cancer and is rarely associated with gastrointestinal perforation, perforation being more frequent in the primary tumor site or at the anastomotic level. We present...
| Autor principal: | |
|---|---|
| Outros Autores: | , , |
| Formato: | report |
| Idioma: | eng |
| Publicado em: |
2017
|
| Assuntos: | |
| Texto completo: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S2341-45452017000600006 |
| País: | Portugal |
| Oai: | oai:scielo:S2341-45452017000600006 |